Dr. Indranil Biswas   
Fulbright-Nehru Project Title: "The Rise of Antibiotic Resistant Bacteria: A Mechanistic
Insight into the Novel Resistance"
Field of Study: Science and Technology
Home Institution in US: University of Kansas, Kansas City, KS
Host Institution in India: Christian Medical College, Vellore  
Start date/Month in India: March 2014
Duration of grant: Four months

Brief Bio:
Dr. Indranil Biswas received his BSc (Ag) Hons degree from BCKV University, India and MSc degree in biotechnology from Madurai Kamaraj University, India. He received his PhD in microbiology from University Paris VII, France. After completing his graduate studies, he joined National Institutes of Health (NIH) in Bethesda, Maryland for his post-doctoral training. In 1998 he joined National Centre for Cell Science, Pune, India as a senior scientist but left the position in 2000 to join the faculty at Emory University and then at University of South Dakota. Currently, he is a professor in the Department of Microbiology at the University of Kansas Medical Center. His main research interest is in the areas of bacterial pathogenesis and bacterial antibiotic resistance. He has over 40 peer reviewed research articles, reviews and book chapters. He serves as editor of two international journals including PLoS, as editorial board member of many international journals including ASM journals, and also serves as reviewer in many NIH Study Sections. His current research program is supported by NIH and other agencies.

Dr. Biswas' Fulbright research is directed towards understanding the molecular mechanisms of NMD-1 (New Delhi metallo-beta-lactamase-1) acquisition by pathogens, NMD-1 gene dispersion, the spectrum of pathogens that are able to acquire NDM-1, and identifying the means to stop the spread. The NDM-1 gene is acquired by many pathogens from the environment and transferred to other emerging pathogens including Acinetobacter baumannii. Emergence of antibiotic resistance pathogens is a growing concern in India due to extensive and frequent use of antibiotics for treating human diseases. The origin of an NDM-1 organism in India highlights the importance of evolution of new drug resistant pathogens in healthcare.